Preclinical in vitro models of breast cancer cells exhibiting ABCC1 (multidrug resistance protein 1) expression exhibited 256-fold increased resistance to T-DM1 after three months of cyclical treatment [114]. This evidence concerns the gene ABCC1 and breast carcinoma.